January 18, 2017 9:26 AM ET

Biotechnology

Company Overview of Kadmon Holdings, LLC

Company Overview

Kadmon Holdings, LLC, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics to address unmet medical needs. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; co-promotes a product for chronic weight management; distributes products for chorea, cytomegalovirus retinitis, and for the prevention of CMV disease. It is also developing product candidates in autoimmune and fibrotic diseases, oncology, and genetic diseases. The company is headquartered in New York, New York.

450 East 29th Street

New York, NY 10016

United States

124 Employees

Phone:

212-308-6000

Fax:

646-666-7978

Key Executives for Kadmon Holdings, LLC

Chief Executive Officer, President and Director
Age: 63
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice President
Age: 32
Total Annual Compensation: $515.4K
Chief Administrative, Compliance & Legal Officer, Executive Vice President and General Counsel
Age: 48
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2015.

Kadmon Holdings, LLC Key Developments

Kadmon Holdings, LLC Terminates Employment Agreement of Zhenping Zhu, Executive Vice President, Biologics

On January 6, 2017, Kadmon Holdings Inc. and Zhenping Zhu, M.D., Ph.D., the Company's Executive Vice President, Biologics, agreed that, effective immediately, his employment with the Company will terminate.

Kadmon Holdings, Inc. Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to U.S. Food and Drug Administration

Kadmon Holdings Inc. announced that it has submitted an Abbreviated New Drug Application (ANDA) for KD034, to the U.S. Food and Drug Administration (FDA). This is the first application submitted to the FDA by any company for a generic trientine hydrochloride product for the treatment of Wilson’s disease in patients who are intolerant of penicillamine. Wilson’s disease is a genetic liver disease characterized by an inability to excrete copper, causing severe hepatic, neurologic, psychiatric and ophthalmic abnormalities.

Kadmon Holdings, LLC Presents at 28th Annual Piper Jaffray Healthcare Conference, Nov-30-2016 08:00 AM

Kadmon Holdings, LLC Presents at 28th Annual Piper Jaffray Healthcare Conference, Nov-30-2016 08:00 AM. Venue: The Lotte New York Palace, 50th St. and Madison Avenue, New York, New York, United States. Speakers: Harlan W. Waksal, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Kadmon Holdings, LLC, please visit www.kadmon.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.